866-997-4948(US-Canada Toll Free)

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Sep 2012

Category :

Head and Neck Cancer

No. of Pages : 103 Pages

 

Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2012

 

Global Markets Directs, \'Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. 

 

It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma. Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer Squamous Cell Carcinoma.
  • A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Head And Neck Cancer Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma 10
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies 12
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Development by Companies 19
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Investigation by Universities/Institutes 20
Companies Involved in Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development 21
AstraZeneca PLC 21
Eli Lilly and Company 22
Viralytics Ltd. 23
GlaxoSmithKline plc 24
YM BioSciences Inc. 25
Symphogen A/S 26
Novartis AG 27
ImClone Systems Incorporated 28
Cell Therapeutics, Inc. 29
Celgene Corporation 30
Idera Pharmaceuticals, Inc. 31
PCI Biotech Holding ASA 32
VentiRx Pharmaceuticals, Inc. 33
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
IMO-2055Rx - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cetuximab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
brostallicin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Amphinex + Bleomycin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Sym-004 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CVA-21 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Tykerb - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Vorinostat + Capecitabine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Erbitux + Avastin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
saracatinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Gleevec + Taxotere - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IMO-2055 + Erbitux - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Lenalidomide + Cetuximab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cetuximab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Tarceva + RAD001 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Theracim + Radiation Therapy - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Cetuximab + Lenalidomide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
LY-2606368 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Tykerb + Cisplatin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ZD6474 + Cisplatin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Paclitaxel Poliglumex + Cetuximab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cetuximab + Sunitinib malate + Radiation therapy - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 74
Docetaxel + Gemcitabine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Erbitux + Cisplatin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
VTX-2337 + Cetuximab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Erlotinib Hydrochloride + Linsitinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Erlotinib Hydrochloride - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Linsitinib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Nimorazole + Radiotherapy - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
BYL-719 + Cetuximab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Carboplatin + Paclitaxel + Lapatinib - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Carboplatin + Paclitaxel + Lapatinib + Cisplatin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
S-1 + Docetaxel + Cisplatin - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 94
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 100
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 101
 

Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103

List of Table


Number of Products Under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2012 10
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
AstraZeneca PLC, H2 2012 21
Eli Lilly and Company, H2 2012 22
Viralytics Ltd., H2 2012 23
GlaxoSmithKline plc, H2 2012 24
YM BioSciences Inc., H2 2012 25
Symphogen A/S, H2 2012 26
Novartis AG, H2 2012 27
ImClone Systems Incorporated, H2 2012 28
Cell Therapeutics, Inc., H2 2012 29
Celgene Corporation, H2 2012 30
Idera Pharmaceuticals, Inc., H2 2012 31
PCI Biotech Holding ASA, H2 2012 32
VentiRx Pharmaceuticals, Inc., H2 2012 33
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 39
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 94
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 100
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Dormant Products 101

List of Chart


Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2012 10
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *